AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24939355 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-study group using MP3 players containing heart sound audio files
Number of subjects: 83
Study 24939355 — intervention group
Group type: COMPARATOR
Intervention: Multimedia lecture group receiving a 1-time 1-hour higher cognitive load lecture using the same audio files
Number of subjects: 83
Study 22381949 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide (400 mg)
Number of subjects: 117
Study 22381949 — intervention group
Group type: COMPARATOR
Intervention: clomipramine (150 mg)
Number of subjects: 117
Study 20467014 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal optimization of surgical care
Number of subjects: 63
Study 20467014 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative management
Number of subjects: 63
Study 17983723 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS intervention
Number of subjects: 42
Study 17983723 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study 16208799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral‐B ProfessionalCare 7000 (PC 7000)
Number of subjects: 70
Study 16208799 — intervention group
Group type: COMPARATOR
Intervention: Crest SpinBrush Pro (SBP)
Number of subjects: 70
Study 12439787 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg daily for three months
Number of subjects: 51
Study 12439787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12439787 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg continued for another nine months with medroxyprogesterone for ten days every three months
Number of subjects: 51
Study 10080612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m2, 30-minute infusion daily for 5 days every 21 days)
Number of subjects: 211
Study 10080612 — intervention group
Group type: COMPARATOR
Intervention: CAV (cyclophosphamide 1,000 mg/m2, doxorubicin 45 mg/m2, vincristine 2 mg, infused on day 1 every 21 days)
Number of subjects: 211
Study 7742676 — intervention group
Group type: EXPERIMENTAL
Intervention: Health checks performed by nurses in primary care
Number of subjects: 2205
Study 2248508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for eight weeks (2 mg/kg/day)
Number of subjects: 73
Study 2248508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for twelve weeks (2 mg/kg/day)
Number of subjects: 73
Study 7002163 — intervention group
Group type: COMPARATOR
Intervention: Fenbufen
Number of subjects: 3457
Study 31847536 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (smoking cessation treatment)
Number of subjects: 179
Study 30675926 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspection and polypectomy during both insertion and withdrawal
Number of subjects: 421
Study 30675926 — intervention group
Group type: COMPARATOR
Intervention: Inspection and polypectomy entirely during withdrawal
Number of subjects: 421
Study 28105737 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily tooth brushing with a rotating-oscillating power toothbrush (Oral-B Professional Care 1000™)
Number of subjects: 54
Study 28105737 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) by caregivers
Number of subjects: 54
Study 25779774 — intervention group
Group type: EXPERIMENTAL
Intervention: Los Angeles Fast-Food Ban
Number of subjects: 0
Study 25779774 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft drink consumption
Number of subjects: 0
Study 23466649 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF), 300 mg orally per day
Number of subjects: 400
Study 23466649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 21097811 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for C trachomatis by means of a sample obtained at home and mailed to the laboratory
Number of subjects: 4000
Study 21097811 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 4000
Study 19740418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 428
Study 19740418 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 428
Study 17099526 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed intramedullary nailing
Number of subjects: 18
Study 17099526 — intervention group
Group type: COMPARATOR
Intervention: Reamed intramedullary nailing
Number of subjects: 18
Study 15682845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regional blockade therapy consisting of dexamethasone and lidocaine
Number of subjects: 26
Study 15682845 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 healthy subjects)
Number of subjects: 26
Study 11417025 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 2
Study 11417025 — intervention group
Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 2
Study 9582556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral daily calcitriol 0.5 micrograms/die (Treatment A)
Number of subjects: 16
Study 9582556 — intervention group
Group type: EXPERIMENTAL
Intervention: Three oral boluses of 2 micrograms of calcitriol a week (Treatment B)
Number of subjects: 16
Study 9582556 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral bolus of 2 micrograms of calcitriol a week (Treatment C)
Number of subjects: 16
Study 9582556 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients, mean age 47 +/- 12 years, creatinine clearances of 21 +/- 12 ml/min)
Number of subjects: 16
Study 7812699 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoscintigraphy (IS) using iodine‐131 anti‐carcinoembryonic antigen (CEA) and anti‐carbohydrate 19‐9 (CA 19-9) monoclonal antibody
Number of subjects: 17
Study 7812699 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT-scan)
Number of subjects: 17
Study 3046584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavitron Biotronics tonometer
Number of subjects: 75
Study 3046584 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 75
Study 30845365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronic acid 70 mg once weekly (n=215)
Number of subjects: 421
Study 30845365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=206)
Number of subjects: 421
Study 30845365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronic acid
Number of subjects: 421
Study 30427494 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% mangosteen peel extract gel (MP-40)
Number of subjects: 150
Study 30427494 — intervention group
Group type: COMPARATOR
Intervention: No treatment (negative-control)
Number of subjects: 150
Study 30427494 — intervention group
Group type: COMPARATOR
Intervention: Bleaching + no treatment (positive-control)
Number of subjects: 150
Study 30427494 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate (SA)
Number of subjects: 150
Study 30427494 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% mangosteen peel extract gel (MP-10)
Number of subjects: 150
Study 30427494 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mangosteen peel extract gel (MP-20)
Number of subjects: 150
Study 26657597 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine combined with psychosocial interventions
Number of subjects: 1154
Study 25326508 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit-positive-age-stereotype-intervention
Number of subjects: 100
Study 25326508 — intervention group
Group type: COMPARATOR
Intervention: Explicit-positive-age-stereotype-intervention
Number of subjects: 100
Study 25326508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined implicit- and explicit-positive-age-stereotype-intervention
Number of subjects: 100
Study 25326508 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 22924334 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (n = 211)
Number of subjects: 598
Study 22924334 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (n = 194)
Number of subjects: 598
Study 22924334 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk drinkers (n = 102)
Number of subjects: 598
Study 20426604 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 101
Study 20426604 — intervention group
Group type: COMPARATOR
Intervention: Music therapy
Number of subjects: 101
Study 18062165 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 24
Study 16131892 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine scrub and isopropyl alcohol paint (Group 2)
Number of subjects: 127
Study 16131892 — intervention group
Group type: COMPARATOR
Intervention: Povidone‐iodine scrub and paint (Group 1)
Number of subjects: 127
Study 10646148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nikon Retinomax handheld autorefractor
Number of subjects: 0
Study 10646148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nikon Retinomax handheld autorefractor under cycloplegia
Number of subjects: 0
Study 10646148 — intervention group
Group type: EXPERIMENTAL
Intervention: Nikon Retinomax handheld autorefractor without cycloplegia
Number of subjects: 0
Study 9301413 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 enriched foods (EPA and DHA)
Number of subjects: 9
Study 9301413 — intervention group
Group type: COMPARATOR
Intervention: Control foods (unenriched)
Number of subjects: 9
Study 8112481 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 0
Study 8112481 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 50 mg
Number of subjects: 0
Study 8112481 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 0
Study 3772925 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional-taught 12-h arthritis self-management courses
Number of subjects: 100
Study 3772925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay-taught 12-h arthritis self-management courses
Number of subjects: 100
Study 3772925 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 3045027 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cisapride i.v.
Number of subjects: 20
Study 3045027 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study 31868130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycra sleeve plus rehabilitation
Number of subjects: 20
Study 31868130 — intervention group
Group type: COMPARATOR
Intervention: Only-rehabilitation group
Number of subjects: 20
Study 28853979 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day for 6 months
Number of subjects: 27
Study 28853979 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 27
Study 28505994 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine Balance 3D system
Number of subjects: 24
Study 28505994 — intervention group
Group type: COMPARATOR
Intervention: Bridge exercise
Number of subjects: 24
Study 25872776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic manual rotation
Number of subjects: 254
Study 25872776 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 254
Study 23505166 — intervention group
Group type: EXPERIMENTAL
Intervention: Different criteria for accelerometry data reduction
Number of subjects: 2240
Study 21091877 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg/day for up to 34 weeks
Number of subjects: 514
Study 21091877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 21091877 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 514
Study 19409710 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase (n=21)
Number of subjects: 38
Study 19409710 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase (n=17)
Number of subjects: 38
Study 19409710 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving at wake-up
Number of subjects: 38
Study 16267603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg in the morning, placebo at bedtime
Number of subjects: 15
Study 16267603 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg at bedtime, placebo in the morning
Number of subjects: 15
Study 16267603 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose) in the morning, amitriptyline 25 mg at bedtime
Number of subjects: 15
Study 15573829 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and strength exercise
Number of subjects: 95
Study 15573829 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal living)
Number of subjects: 95
Study 11549985 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 188
Study 11549985 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol 0.25%
Number of subjects: 188
Study 9219471 — intervention group
Group type: EXPERIMENTAL
Intervention: Capiox E oxygenator with nonpulsatile (NP) blood pump
Number of subjects: 90
Study 9219471 — intervention group
Group type: EXPERIMENTAL
Intervention: Capiox E oxygenator with pulsatile (PP) blood pump
Number of subjects: 90
Study 9219471 — intervention group
Group type: EXPERIMENTAL
Intervention: Capiox E oxygenator (both PP and NP)
Number of subjects: 90
Study 9219471 — intervention group
Group type: COMPARATOR
Intervention: Maxima and Ultrox oxygenators
Number of subjects: 90
Study 9219471 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxima oxygenator
Number of subjects: 90
Study 9219471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrox oxygenator
Number of subjects: 90
Study 9219471 — intervention group
Group type: EXPERIMENTAL
Intervention: Capiox E oxygenator
Number of subjects: 90
Study 8354978 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery or percutaneous transluminal renal angioplasty (PTRA)
Number of subjects: 81
Study 8354978 — intervention group
Group type: COMPARATOR
Intervention: Renal artery stenosis (RAS) patients
Number of subjects: 81
Study 8354978 — intervention group
Group type: COMPARATOR
Intervention: Patients with severe hypertension lacking significant renal artery stenosis
Number of subjects: 81
Study 3304951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate at a dosage of 1600 mg/day
Number of subjects: 16
Study 3304951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30794622 — intervention group
Group type: EXPERIMENTAL
Intervention: Best ESRF prediction model including age, gender, eGFR and albuminuria
Number of subjects: 1970
Study 30794622 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of ethnicity to the prediction model
Number of subjects: 1970
Study 30794622 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up period
Number of subjects: 1970
Study 30794622 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident ESRF
Number of subjects: 1970
Study 28498501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 30
Study 28498501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 30
Study 24289224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg BID
Number of subjects: 197
Study 24035327 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CCRT) with fluorouracil (5‐FU) plus mitomycin
Number of subjects: 620
Study 21346001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist pergolide given orally
Number of subjects: 24
Study 18434638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 176
Study 18434638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 18434638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 176
Study 16271818 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions with a hint
Number of subjects: 0
Study 16271818 — intervention group
Group type: COMPARATOR
Intervention: Instructions without a hint
Number of subjects: 0
Study 12582754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure (LP) pneumoperitoneum (7 mmHg)
Number of subjects: 148
Study 12582754 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure (SP) pneumoperitoneum (12 mmHg)
Number of subjects: 148
Study 11220553 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (initial dosage of 5 mg/day titrated up by 5 mg biweekly through week 6, maintained at 20 mg through week 24)
Number of subjects: 175
Study 11220553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 11220553 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 175
Study 9123738 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combination therapy with flutamide and LHRH agonist for 3 months before radical prostatectomy
Number of subjects: 161
Study 9123738 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 161
Study 8473453 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (0.75 mg for two doses 12 h apart)
Number of subjects: 834
Study 8473453 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe regimen
Number of subjects: 834
Study 3768488 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate salt of naftidrofuryl
Number of subjects: 0
Study 3768488 — intervention group
Group type: COMPARATOR
Intervention: Oxalate salt of naftidrofuryl
Number of subjects: 0
Study 29533154 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered care transition intervention (n = 85)
Number of subjects: 171
Study 29533154 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care control (n = 86)
Number of subjects: 171
Study 27245783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic lidocaine and dexamethasone (ITLD) injection
Number of subjects: 40
Study 27245783 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic saline injection (Control)
Number of subjects: 40
Study 24723218 — intervention group
Group type: EXPERIMENTAL
Intervention: Group art therapy
Number of subjects: 140
Study 24723218 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 140
Study 22745140 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoid (30 mg 3 times daily)
Number of subjects: 80
Study 22745140 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (25 mg 3 times daily)
Number of subjects: 80
Study 19119067 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval swimming at S(200-400) (1.28±0.05 m/s)
Number of subjects: 12
Study 18087561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic and lipid control
Number of subjects: 116
Study 18087561 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 116
Study 18087561 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 116
Study 18087561 — intervention group
Group type: COMPARATOR
Intervention: No statins
Number of subjects: 116
Study 15814551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205
Study 15814551 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin-ME
Number of subjects: 205
Study 15814551 — intervention group
Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 205
Study 12405240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 12405240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9849102 — intervention group
Group type: EXPERIMENTAL
Intervention: System Responsiveness (SR) with a focus on Standard Deviation of System Responsiveness (SDSR) above 82 ms
Number of subjects: 33
Study 9849102 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement tasks requiring visual feedback
Number of subjects: 33
Study 8205863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 31
Study 8205863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2684384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoguazone (MGBG)
Number of subjects: 52
Study 2684384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine (VLB)
Number of subjects: 52
Study 4415722 — intervention group
Group type: EXPERIMENTAL
Intervention: High Disinhibitors
Number of subjects: 49
Study 4415722 — intervention group
Group type: COMPARATOR
Intervention: Low Disinhibitors
Number of subjects: 49
Study 4415722 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinhibition subscale of the SSS
Number of subjects: 49
Study 4415722 — intervention group
Group type: EXPERIMENTAL
Intervention: Other subscales of the SSS
Number of subjects: 49
Study 31099215 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture nerve stimulation therapy (ENST), 50 min per session, three times a week for 3 months
Number of subjects: 68
Study 31099215 — intervention group
Group type: COMPARATOR
Intervention: Perfusion therapy of four‐medication combination (heparin sodium, lidocaine, sodium bicarbonate, gentamicin sulfate), twice a week for the first 6‐8 weeks, then twice per month for 3 months
Number of subjects: 68
Study 28530451 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Volume Injection (HVI)
Number of subjects: 60
Study 28530451 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 60
Study 28530451 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 26698295 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiobesity advertisements emphasizing individual responsibility
Number of subjects: 162
Study 26698295 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of overweight individuals
Number of subjects: 162
Study 26698295 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of fast food
Number of subjects: 162
Study 26698295 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigmatizing images of overweight individuals
Number of subjects: 162
Study 24451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported IBD diagnosis
Number of subjects: 450
Study 24451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported disease location for Crohn's disease
Number of subjects: 450
Study 24451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported presence of perianal disease for Crohn's disease
Number of subjects: 450